Strengthening Evidence on Optimal Multidrug-resistant Tuberculosis Treatment Regimens
Harvard Medical School (HMS and HSDM)
Abstract
This is a multisite prospective cohort study of patients with multidrug- or rifampin-resistant tuberculosis who are treated with an all-oral shortened regimen under routine program conditions in one of three countries (Peru, Lesotho, Kazakhstan).
MeSH terms
- Tuberculosis, Multidrug-Resistant